174 related articles for article (PubMed ID: 12237745)
1. On the role of monoamine oxidase-A for the maintenance of the volitional consumption of ethanol in two different rat models.
Mega BT; Sheppard KW; Williams HL; McMillen BA
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):319-26. PubMed ID: 12237745
[TBL] [Abstract][Full Text] [Related]
2. Alcohol consumption alters monoamine oxidase activities in brain structures: relation to ethanol craving.
Zimatkin SM; Tsydik VF; Lelevich VV
Cas Lek Cesk; 1997 Nov; 136(21):666-9. PubMed ID: 9444785
[TBL] [Abstract][Full Text] [Related]
3. The MAO-A inhibitor clorgyline reduces ethanol-induced locomotion and its volitional intake in mice.
Ledesma JC; Escrig MA; Pastor R; Aragon CM
Pharmacol Biochem Behav; 2014 Jan; 116():30-8. PubMed ID: 24252443
[TBL] [Abstract][Full Text] [Related]
4. The effect of ethanol consumption on the sensitivity of rat brain monoamine oxidases to the inhibition by pargyline in vivo and in vitro.
Panova NG; Axenova LN; Medvedev AE
Neurobiology (Bp); 2000; 8(3-4):225-30. PubMed ID: 11225512
[TBL] [Abstract][Full Text] [Related]
5. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.
Guillem K; Vouillac C; Azar MR; Parsons LH; Koob GF; Cador M; Stinus L
Eur J Neurosci; 2006 Dec; 24(12):3532-40. PubMed ID: 17229101
[TBL] [Abstract][Full Text] [Related]
7. FA-70, a novel selective and irreversible monoamine oxidase-A inhibitor: effect on monoamine metabolism in mouse cerebral cortex.
Morón JA; Pérez V; Pastó M; Lizcano JM; Unzeta M
J Pharmacol Exp Ther; 2000 Feb; 292(2):788-94. PubMed ID: 10640319
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
9. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoamine oxidase isoforms modulates nicotine withdrawal syndrome in the rat.
Malin DH; Moon WD; Goyarzu P; Barclay E; Magallanes N; Vela AJ; Negrete AP; Mathews H; Stephens B; Mills WR
Life Sci; 2013 Oct; 93(12-14):448-53. PubMed ID: 23988853
[TBL] [Abstract][Full Text] [Related]
12. Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters.
Adjou KT; Dilda P; Aumond P; Gueddari S; Deslys JP; Dormont D; Seman M
Neurochem Int; 2008 Jun; 52(8):1416-21. PubMed ID: 18442871
[TBL] [Abstract][Full Text] [Related]
13. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
[TBL] [Abstract][Full Text] [Related]
14. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors].
Maki Y
Hokkaido Igaku Zasshi; 2001 May; 76(3):133-42. PubMed ID: 11481866
[TBL] [Abstract][Full Text] [Related]
15. Effects of the non-competitive NMDA receptor antagonist memantine on the volitional consumption of ethanol by alcohol-preferring rats.
Malpass GE; Williams HL; McMillen BA
Basic Clin Pharmacol Toxicol; 2010 May; 106(5):435-44. PubMed ID: 20210793
[TBL] [Abstract][Full Text] [Related]
16. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor.
White HL; Ascher JA
Clin Neuropharmacol; 1993; 16 Suppl 2():S25-33. PubMed ID: 8313394
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.
Guang HM; Du GH
Acta Pharmacol Sin; 2006 Jun; 27(6):760-6. PubMed ID: 16723097
[TBL] [Abstract][Full Text] [Related]
19. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Weinstock M; Poltyrev T; Bejar C; Youdim MB
Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
[TBL] [Abstract][Full Text] [Related]
20. Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A.
Alves E; Summavielle T; Alves CJ; Custódio JB; Fernandes E; de Lourdes Bastos M; Tavares MA; Carvalho F
Addict Biol; 2009 Apr; 14(2):185-93. PubMed ID: 19076925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
